SCHEMBL3634671

SCHEMBL3634671

CCCNc1c(N)cccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.41
TRPA1 O75762 2/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 2/20 0.39
CYP1A2 P05177 2/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPK14 Q16539 1/20 0.35
APP P05067 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
CYP3A4 P08684 2/20 0.35
NPC1 O15118 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX12 P18054 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19121210 0.86 TRPA1 (0.44) HDAC1TRPA1KDM4EGAACYP1A2
SCHEMBL13497802 0.85 HDAC1 (0.43) HDAC1TRPA1KDM4EGAAALDH1A1
SCHEMBL11660041 0.79 TRPA1 (0.43) TRPA1CYP1A2ALDH1A1MAPK14DRD2
SCHEMBL3635788 0.79 CD44 (0.43) KDM4EGAACYP1A2ALDH1A1MAPK14
SCHEMBL20810767 0.78 IDO1 (0.42) KDM4EGAAALDH1A1APPDRD2
SCHEMBL3633711 0.78 ALDH1A1 (0.44) KDM4EGAAALDH1A1MAPK14APP
SCHEMBL2217183 0.77 HDAC1 (0.39) HDAC1KDM4ECYP1A2ALDH1A1KMT2A
SCHEMBL2991540 0.75 PTGES2 (0.45) TRPA1KMT2A
SCHEMBL28097102 0.75 SMN1; SMN2 (0.44) HDAC1KDM4EALDH1A1DRD2DRD3
SCHEMBL4929104 0.74 HDAC1 (0.46) HDAC1GAAALDH1A1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 HDAC1 125/4885TRPA1 105/4885KDM4E 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.